Six-week oral ketamine treatment for chronic suicidality is associated with increased grey matter volume.
Depression
Glutamate
Magnetic resonance imaging (MRI)
Journal
Psychiatry research. Neuroimaging
ISSN: 1872-7506
Titre abrégé: Psychiatry Res Neuroimaging
Pays: Netherlands
ID NLM: 101723001
Informations de publication
Date de publication:
30 11 2021
30 11 2021
Historique:
received:
21
05
2021
revised:
24
07
2021
accepted:
18
08
2021
pubmed:
31
8
2021
medline:
29
3
2022
entrez:
30
8
2021
Statut:
ppublish
Résumé
Chronic suicidality has been associated with neuronal atrophy in cortico-striato-limbic regions and is thought to be mediated via a glutamatergic imbalance. Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has been posited to exert anti-suicidal effects by promoting neurogenesis via modulation of glutamatergic transmission. This voxel-based morphometry study examined the effect of ketamine on whole brain grey matter in adults with chronic suicidality. Grey matter in the periaqueductal grey, nucleus accumbens, putamen, caudate, and thalamus was significantly increased following 6 weeks of low dose oral ketamine treatment. These results support the notion that ketamine rapidly enhances synaptic plasticity within striato-limbic regions.
Identifiants
pubmed: 34461430
pii: S0925-4927(21)00121-9
doi: 10.1016/j.pscychresns.2021.111369
pii:
doi:
Substances chimiques
Receptors, N-Methyl-D-Aspartate
0
Ketamine
690G0D6V8H
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
111369Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.